Abstract: After IFN withdrawal, viraemia transiently increased to high levels in five of 11 (45%) patients who showed rt M204V/I lamivudine mutant resistant.
Hepatitis B Virus preS/S Truncation Mutant rtM204I/sW196* Increases Carcinogenesis through Deregulated HIF1A, MGST2, and TGFbi.
Abstract: The major HBV lamivudine (LMV)-resistant mutations in the polymerase gene within the reverse transcriptase (rt) region at rtM204V or rtM204I are associated with changes in the overlapping envelope gene products, in particular, the gene encoding small envelope protein (s) at sI195M or sW196L/S/Stop.
Virus and transaminase levels determine the emergence of drug resistance during long-term lamivudine therapy in chronic hepatitis B.
Abstract: BACKGROUND/AIMS: The results of earlier studies on determinants for the emergence of tyrosine-methionine-aspartate-aspartate (YMDD) mutants (rtM204 I/V) were controversial.
Abstract: RESULTS: rtM204 I/V emerged in 37 noncirrhotic and 36 cirrhotic patients.
Abstract: Stepwise logistic regression analysis showed that baseline hepatitis B e antigen (HBeAg) status [odds ratio (OR), 7.728; 95% confidental interval (CI), 2.886-12.957; P=0.0026], HBV-DNA level (OR, 3.756; 95% CI, 1.058-5.089; P=0.0202), alanine transaminase (ALT) level (OR, 6.285; 95% CI, 1.057-11.990; P=0.00246) and treatment duration (OR, 19.88; 95% CI, 8.652-31.762; P<0.0004)
Evaluation of methods for monitoring drug resistance in chronic hepatitis B patients during lamivudine therapy based on mass spectrometry and reverse hybridization.
Abstract: A total of 60 patient samples were analysed for the presence of mutations at rtL1 80M and rtM204I/V of HBV polymerase by the LiPA and RFMP assays.
Abstract: The ability to detect mutations at rtM204I/V was compared with defined mixtures of wild-type and mutant HBV cloned in plasmids at relative concentrations ranging from 1-25%.
Changes in different regions of hepatitis B virus gene in hepatitis B 'e' antigen-negative patients with chronic hepatitis B: the effect of long-term lamivudine therapy.
Abstract: YMDD mutations were observed in nine cases and both, L180M and M204V/I mutations were simultaneously detected in six cases.
Abstract: About 75% of the patients with M204V mutations were responders and none with M204I or mixed pattern sustained response.
Overlapping gene mutations of hepatitis B virus in a chronic hepatitis B patient with hepatitis B surface antigen loss during lamivudine therapy.
PMID: 15953865
2005
Journal of Korean medical science
Abstract: Methionine of rtM204 in the P gene was substituted for isoleucine indicating YIDD mutation (rtM204I).
Result: A mutation in the YMDD (tyrosine, methionine, aspartate, aspartate) motif of the viral polymerase (reverse transcriptase [rt]) was noticed as methionine 204 to isoleucine (rtM204I).
Hepatitis B Virus preS/S Truncation Mutant rtM204I/sW196* Increases Carcinogenesis through Deregulated HIF1A, MGST2, and TGFbi.
PMID: 15973769
2005
Journal of Zhejiang University. Science. B
Abstract: Among them, 45 patients had rtL180M/M204V mutation (41.28%), 28 patients had rtL180M/M204I mutation (25.70%) and 36 patients had rtM204I mutation (33.02%).
Emergence of a novel mutation in the FLLA region of hepatitis B virus during lamivudine therapy.
PMID: 15980328
2005
Antimicrobial agents and chemotherapy
Abstract: The major mechanism of resistance has been attributed to the alteration in the YMDD motif of the HBV polymerase due to an amino acid change of rtM204 to V/I and an accompanying rtL180M conversion.
Abstract: The mutant had a rtL180C/M204I genotype and was detected after 2 years of therapy with lamivudine.
Abstract: The resistance profile was comparable to that of the previously reported rtL180 M/M204I-containing virus.
Abstract: Transient transfection studies in human hepatoma cell
Response to long-term lamivudine treatment (up to 5 years) in patients with severe chronic hepatitis B, role of genotype and drug resistance.
Abstract: To investigate this in vitro, we generated novel stable cell lines expressing HBV encoding the four major patterns of lamivudine resistance mutations (rtL180M+rtM204V, rtV173L+rtL180M+rtM204V, rtM204I and rtL180M+ rtM204I).
HBV mutation literature information.
PMID: 
2005
Journal of viral hepatitis
Browser Board
Co-occurred Entities
Filtrator
ViMRT